Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Slides:

Advertisements

Similar presentations

Volume 60, Issue 4, Pages (October 2011)

Advertisements

Volume 70, Issue 2, Pages (August 2016)

Volume 68, Issue 4, Pages (October 2015)

Volume 60, Issue 5, Pages (November 2011)

Volume 58, Issue 2, Pages (August 2010)

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Volume 62, Issue 4, Pages (October 2012)

Volume 70, Issue 6, Pages (December 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 60, Issue 2, Pages (August 2011)

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Volume 51, Issue 1, Pages (January 2007)

Volume 52, Issue 3, Pages (September 2007)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 1, Pages 4-6 (January 2016)

European Urology Oncology

Volume 74, Issue 2, Pages (August 2018)

Volume 68, Issue 1, Pages (July 2015)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 51, Issue 5, Pages (May 2007)

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 2, Pages (February 2017)

Giuseppe Di Lorenzo, Riccardo Autorino, Cora N. Sternberg

Volume 66, Issue 3, Pages (September 2014)

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 65, Issue 5, Pages (May 2014)

Volume 66, Issue 2, Pages (August 2014)

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Volume 65, Issue 3, Pages (March 2014)

Volume 71, Issue 3, Pages (March 2017)

Volume 70, Issue 5, Pages (November 2016)

Volume 65, Issue 6, Pages (June 2014)

Volume 61, Issue 6, Pages (June 2012)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

Volume 74, Issue 3, Pages (September 2018)

Volume 70, Issue 2, Pages (August 2016)

Volume 74, Issue 2, Pages (August 2018)

Volume 68, Issue 4, Pages (October 2015)

Volume 70, Issue 2, Pages (August 2016)

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 68, Issue 4, Pages (October 2015)

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma Sergio Bracarda, Alain Ravaud, Marino.

Current and Future Trends in the Treatment of Renal Cancer

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

European Urology Oncology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 70, Issue 6, Pages (December 2016)

Bernard Escudier European Urology Supplements

Volume 74, Issue 3, Pages (September 2018)

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Volume 68, Issue 5, Pages (November 2015)

Volume 52, Issue 4, Pages (October 2007)

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

European Urology Oncology

Volume 76, Issue 1, Pages (July 2019)

European Urology Oncology

European Urology Oncology

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Autologous Stem Cell Transplantation for POEMS Syndrome

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic, Ronit Simantov European Urology Volume 70, Issue 6, Pages 1006-1015 (December 2016) DOI: 10.1016/j.eururo.2016.05.010 Copyright © 2016 Terms and Conditions

Fig. 1 Receiver operating characteristic analysis of overall survival and progression-free survival. Vascular endothelial growth factor–targeted agents include axitinib, bevacizumab plus temsirolimus, sorafenib, and sunitinib. Treatment with temsirolimus includes both single-agent temsirolimus and temsirolimus plus interferon α. D=point with shortest distance to the optimal point; IFN=interferon; OS=overall survival; PFS=progression-free survival; VEGF=vascular endothelial growth factor. European Urology 2016 70, 1006-1015DOI: (10.1016/j.eururo.2016.05.010) Copyright © 2016 Terms and Conditions

Fig. 2 Kaplan-Meier estimates. (a) Overall survival and (b) progression-free survival in patients with and without early tumour shrinkage; (c) OS and (d) PFS in patients with or without objective response by Response Evaluation Criteria in Solid Tumours. CI=confidence interval; eTS=early tumour shrinkage; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumours. European Urology 2016 70, 1006-1015DOI: (10.1016/j.eururo.2016.05.010) Copyright © 2016 Terms and Conditions

Fig. 3 Cox proportional hazards analysis of (a) overall survival and (b) progression-free survival. Early tumour shrinkage ≥10% (yes) versus <10% (no). Vascular endothelial growth factor–targeted agents include axitinib, bevacizumab plus temsirolimus, sorafenib, and sunitinib. Treatment with temsirolimus includes both single-agent temsirolimus and temsirolimus plus interferon-α. CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; eTS=early tumour shrinkage; HR=hazard ratio; IFN=interferon; LLN=lower limit of normal; ULN=upper limit of normal; VEGF=vascular endothelial growth factor. European Urology 2016 70, 1006-1015DOI: (10.1016/j.eururo.2016.05.010) Copyright © 2016 Terms and Conditions